Rituximab Studied as Add-On Therapy for New-Onset Myasthenia Gravis

TUESDAY, Oct. 4, 2022 -- A single infusion of rituximab early after the onset of generalized myasthenia gravis improves outcomes at 16 weeks, according to a study published online Sept. 19 in JAMA Neurology.
Fredrik Piehl, M.D., Ph.D., from the...

Source: Drugs.com - Pharma News - October 4, 2022 Category: Pharmaceuticals Source Type: news